Lingxin Meng

2.0k citations
27 papers · 542 indexed · h-index 12
Topics
Peptidase Inhibition and Analysis (7 papers)Radiopharmaceutical Chemistry and Applications (4 papers)Cardiac Structural Anomalies and Repair (4 papers)
Partner nations
ChinaSingaporeDenmark

In The Last Decade

Lingxin Meng

27 papers receiving 538 citations

Peers

Lingxin Meng
Comparison fields: 5 of 76
  • Oncology 182
  • Molecular Biology 171
  • Cancer Research 109
  • Electrical and Electronic Engineering 95
  • Biomedical Engineering 83
Replace Monireh Golpour with:
Monireh Golpour Iran
Hajar Yaghoobi Iran
Wenjie You China
Shino Nakagawa Japan
Mengjia Zhao China
Anca Onaciu Romania
Sankalp Gharat India
Zheng Pan China
Sherif E. Emam Egypt
Zbigniew Pasieka Poland
Lingxin Meng relative to Monireh Golpour Iran Monireh Golpour's profile →
Citations per field
00.5×3.3×
Monireh Golpour · 1×
Citations per year

Countries citing papers authored by Lingxin Meng

Since Specialization
Citations

This map shows the geographic impact of Lingxin Meng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lingxin Meng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lingxin Meng more than expected).

Fields of papers citing papers by Lingxin Meng

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lingxin Meng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lingxin Meng. The network helps show where Lingxin Meng may publish in the future.

Co-authorship network of co-authors of Lingxin Meng

This figure shows the co-authorship network connecting the top 25 collaborators of Lingxin Meng. A scholar is included among the top collaborators of Lingxin Meng based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lingxin Meng. Lingxin Meng is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
#WorkIndexed citations
1 9
2 3
3 3
4 4
5 11
6 3
7 2
8 4
9 6
10 27
11 56
12 46
13 3
14 12
15 1
16 7
17 65
18 25
19 40
20 11

About Lingxin Meng

Lingxin Meng is a scholar working on Oncology, Cancer Research and Immunology, having authored 27 papers that have together received 542 indexed citations. Recurring topics across this work include Peptidase Inhibition and Analysis (7 papers), Radiopharmaceutical Chemistry and Applications (4 papers) and Cardiac Structural Anomalies and Repair (4 papers). The work is most often cited by research in Cancer Research (109 citations), Oncology (182 citations) and Radiology, Nuclear Medicine and Imaging (71 citations). Lingxin Meng has collaborated with scholars based in China, Singapore and Denmark. Frequent co-authors include Jianyang Fang, Zhide Guo, Jingmei Xu, Pengyun Zhao, Zhenguo Zhang, Zhe Wang, Jiahui Ren, Haojun Chen, Qin Lin and Liang Zhao. Their work appears in journals such as Journal of Controlled Release, Journal of Medicinal Chemistry and Journal of Membrane Science.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026